Appointment dossier — Glioblastoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Glioblastoma
- Temozolomide — Human evidence · 2 positive / 2 negative-mixed · PMID 40466642, 36067704, 38672566, 38630257
- Pembrolizumab — Human evidence · 1 positive · PMID 40466642
- Selenium (Stand-alone) — Review evidence · 1 positive · PMID 34121995
- Bevacizumab — Review evidence · 0 positive / 1 negative-mixed · PMID 35806212, 26664126
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07021339 · Phase 3 — Anterior Temporal Lobectomy in Temporal Glioblastoma (Germany)
- NCT05904119 · Phase 3 — Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study (Austria)
- NCT06595186 · Phase 2 — JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) (China)
- NCT06687681 · Phase 2 — Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas (Iran)
- NCT05909618 · Phase 2 — Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (Israel)
- NCT06058988 · Phase 2 — Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer (United States)
- NCT05052957 · Phase 2 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (United States)
- NCT06672575 · Phase 1 / Phase 2 — A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma (United States)
- NCT06936046 · Phase 2 — Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression (China)
- NCT05664464 · Phase 1 / Phase 2 — Glutamate Inhibitors in Glioblastoma (Switzerland)
- NCT06926075 · Phase 1 / Phase 2 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours (Australia)
- NCT07285044 · Phase 2 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (United States)
- NCT07284628 · Phase 2 — Vortioxetine for Newly Diagnosed Glioblastoma (Switzerland)
- NCT05660369 · Phase 1 — CARv3-TEAM-E T Cells in Glioblastoma (United States)
- NCT05366179 · Phase 1 — Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc (United States)
- NCT03896568 · Phase 1 — MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma (United States)
- NCT03911388 · Phase 1 — HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (United States)
- NCT06132438 · Phase 1 — Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (Australia)
Most-relevant first: trials that name Glioblastoma, then broader trials you may still qualify for. 325 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Selenium (Stand-alone) × platinum_chemo (high-stakes) — Monitor (low)
- Selenium (Stand-alone) × antioxidants — Synergize (low)
- Selenium (Stand-alone) × Cisplatin — Synergize (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Temozolomide has been studied in people for Glioblastoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Pembrolizumab has been studied in people for Glioblastoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT07021339), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?